Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

Pfizer's strength lies in its integrated approach to drug development, from discovery to clinical trials, and finally, ...

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted ...

Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to $36.16.Dividend yield and stable revenues prov ...

Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Notes landmark agreement with U.S. government: Says voluntary agreement provides greater clarity; reduces uncertainty around tariffs and pricing; allows investment in future innovation and growth.

Pfizer stands as one of the largest drug makers in the world. It faces normal industry challenges, but it also has a lofty payout ratio. Its latest acquisition shows what it is capable of doing to get ...

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...